Hemoglobin A1c levels and 1-year mortality in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention.

IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Future cardiology Pub Date : 2024-04-11 DOI:10.2217/fca-2023-0121

P. Izadpanah, Tara Dehghanzadeh, A. Attar, Alireza Hosseinpour, Nima Rahimikashkooli

引用次数: 0

Abstract

Background: In this study, we investigated whether different levels of hemoglobin A1c (HbA1c) are associated with different short-term and 1-year mortality rates among diabetic patients undergoing percutaneous coronary intervention. Patients & methods: Clinical events including in-hospital, 1-month and 1-year mortality were compared between three groups based on HbA1c levels of patients (I: ≤5.6%, II: 5.7-6.4%, III: ≥6.5%). Results: Among 165 diabetic individuals, patients with abnormal HbA1c levels (≥6.5%) experienced significantly higher hospitalization days (7.65 ± 1.64 days) compared with those with normal HbA1c (4.94 ± 0.97 days) (p < 0.0001). In-hospital mortality was significantly higher in group III (14.5%) and II (5.5%) compared with group I (0%) (p = 0.008). Conclusion: HbA1c levels may be a reliable predictor of short-term clinical events in diabetic patients.

查看原文本刊更多论文

接受经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者的血红蛋白 A1c 水平与 1 年死亡率。

背景：在这项研究中，我们调查了接受经皮冠状动脉介入治疗的糖尿病患者中，不同的血红蛋白 A1c (HbA1c) 水平是否与不同的短期和 1 年死亡率有关。患者与方法：根据患者的 HbA1c 水平（I：≤5.6%；II：5.7-6.4%；III：≥6.5%），比较三组患者的临床事件，包括院内、1 个月和 1 年死亡率。结果在 165 名糖尿病患者中，HbA1c 水平异常（≥6.5%）的患者住院天数（7.65 ± 1.64 天）明显高于 HbA1c 正常的患者（4.94 ± 0.97 天）（P < 0.0001）。与第一组（0%）相比，第三组（14.5%）和第二组（5.5%）的住院死亡率明显更高（p = 0.008）。结论HbA1c 水平可能是糖尿病患者短期临床事件的可靠预测指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.80

自引率

5.90%

发文量

期刊介绍： Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.